Slide
Slide

About Us

Tonix is a biopharmaceutical company focused on developing novel therapeutics to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases.

Tonix’s development portfolio is focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and acute stress disorder (ASD). Our pipeline is also comprised of immunology, rare disease, and infectious disease product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Our rare disease portfolio includes therapeutics to treat rare genetic conditions. Tonix’s infectious disease portfolio includes a live virus vaccine platform.

Central Nervous System

Tonix’s lead CNS candidate, TNX-102 SL1 (sublingual formulation of cyclobenzaprine) has completed two positive Phase 3 studies for the management of fibromyalgia, a disorder characterized by chronic musculoskeletal pain, sleep deprivation, fatigue and mood changes. TNX-102 SL is also being developed for Long COVID and acute stress disorder (ASD)

Immunology

Tonix’s immunology portfolio includes TNX-1500, an anti-CD40L humanized monoclonal antibody, in development for organ transplant rejection as well as other autoimmune conditions. On the immuno-oncology front, TNX-1700 is in development for gastric and colorectal cancers.

Infectious Disease

Tonix’s lead infectious disease product candidate, TNX-8012, is a live horsepox virus vaccine for percutaneous administration  in development to protect against smallpox and monkeypox. Tonix will continue work on this live virus vector technology as a platform for rapid response to new pathogens.

DNA_2

Rare Disease

TNX-2900, Tonix’s proprietary potentiated intranasal oxytocin, is in development for the treatment of Prader-Willi syndrome (PWS), the most common genetic cause of life-threatening childhood obesity. TNX-2900 has been granted Orphan Drug Designation (ODD) in the US by the FDA for the treatment of PWS.

Our Mission, Vision, and Core Values

Our Mission is to improve population health by inventing and developing innovative therapies and vaccines, through broad in-house capabilities and creative collaborations, to help address important unmet needs. We strive to do this by using our integrated development engine to advance innovative programs across multiple therapeutic areas into the clinic while maximizing asset potential.

Our Vision is to be a leader in providing novel drug therapies and vaccines to improve population health around the world.

Our Core Values reflect our principles and define our culture as we strive to succeed in our mission and vision.

To learn more About Us, view our video.

Our Mission, Vision, and Core Values

Our Mission is to improve population health by inventing and developing innovative therapies and vaccines, through broad in-house capabilities and creative collaborations, to help address important unmet needs. We strive to do this by using our integrated development engine to advance innovative programs across multiple therapeutic areas into the clinic while maximizing asset potential.

Our Vision is to be a leader in providing novel drug therapies and vaccines to improve population health around the world.

Our Core Values reflect our principles and define our culture as we strive to succeed in our mission and vision.

To learn more About Us, view our video.

Tonix Pharmaceuticals is a publicly traded company and is listed on the NASDAQ exchange under the ticker TNXP.

1TNX-102 SL is an investigational new drug and has not been approved for any indication.
2TNX-801 is an investigational new biologics and has not been approved for any indication.